SecBot SecBot
8-K ·Filed Nov 13, 2026

TNDM

TANDEM DIABETES CARE INC
BULLISH
Impact 5/10
Horizonmonths Processed3d 19h ago SEC0001438133-26-000148
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor the commercial launch timeline in H1 2027 and initial adoption rates. The tubeless feature with 7-day wear is a competitive differentiator against other tubeless pumps. Watch for competitor responses and any supply or manufacturing scale-up risks noted in the forward-looking statements.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$20.07
T+0 close · Nov 13, 2026 · via day close
Latest settled
−7.92%
T+1 · $18.48
Vs SPY
−6.01%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $20.07entry
  2. T+1 · 21h ago −7.92%α −6.01% · $18.48
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tandem Diabetes Care received FDA 510(k) clearance for a tubeless cartridge and infusion set for its Tandem Mobi insulin pump, enabling up to 7 days of wear. Commercial launch is planned for the first half of 2027 in the U.S. This expands the product's addressable market by offering a tubeless option alongside the existing tubed configuration.

Key Facts

  • Received FDA 510(k) clearance for Tandem Mobi tubeless cartridge and infusion set on November 12, 2026.
  • Tubeless infusion set cleared for up to 7 days of wear; cartridge cleared for 3 days of use.
  • Full commercial launch planned for first half of 2027 in the United States.
  • Tandem Mobi pump is now cleared for both tubeless and tubed infusion options.
  • The system incorporates Control-IQ+ advanced hybrid closed-loop technology.

Financial Impact

Regulatory clearance for a differentiated tubeless product expands Tandem's addressable market in insulin delivery. No financial figures were provided in the filing.

revenue

Risk Factors

  • Commercial launch is not until H1 2027, with no revenue contribution in the near term.
  • Supply and manufacturing scale-up risks could delay launch or limit initial availability.
  • Competitor products with similar tubeless automated insulin delivery features may erode market share.
  • Regulatory clearance must be maintained; any safety or quality issues could impact the product.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
60% bullish (30 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438133-26-000148
Document: 0001438133-26-000148-index-headers.html0001438133-26-000148
Document: 0001438133-26-000148-index.html0001438133-26-000148
Document: 0001438133-26-000148.txt0001438133-26-000148

Track record

9 reports on TNDM

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $18.50 Now $18.48 +0.11% settles Nov 18
  2. Nov 16, 2026today SC 13G Neutral 4/10 Entry $20.00 Now $18.48 −7.60% settles Nov 17
  3. Nov 13, 20263d ago 8-K Bullish 5/10 Viewing Entry $20.07 to $18.48 Now $18.48 −7.92% ▼ −7.92% −6.01% vs SPY
  4. Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $18.71 to $18.77 Now $18.48 −1.23% ▲ +0.32% −1.00% vs SPY
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $16.91 to $18.17 Now $18.48 +9.28% ▲ +7.45% +5.08% vs SPY
  6. Oct 27, 202620d ago 144 Neutral 2/10 Entry $19.68 to $19.79 Now $18.48 −6.10% ▲ +0.56% +0.94% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $15.80 to $16.60 Now $18.48 +16.96% ▲ +5.06% +4.52% vs SPY
  8. May 15, 202626w ago 8-K Neutral 3/10 Entry $12.82 to $13.53 Now $18.48 +44.15% ▲ +5.54% +5.60% vs SPY
  9. Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $19.35 to $19.68 Now $18.48 −4.50% ▲ +1.71% +1.13% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 5h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026